Gilead Sciences, Inc.

GILD

US3755581036

Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).

Employees

18,000

Sector

Pharmaceuticals

Calendar

03/12/2024 - Piper Sandler Healthcare Conference

More about the company

Income Statement and Estimates

income-statement-evolution-chart GILEAD-SCIENCES-INC

More financial data

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

92.58USD

Average target price

97.28USD

Spread / Average Target

+5.08%

Consensus

Profit revisions

estimates-change-chart GILEAD-SCIENCES-INC

Estimate revisions

Quarterly revenue - Rate of surprise

quality-estimates-chart GILEAD-SCIENCES-INC

Company calendar

Market Closed - Nasdaq Other stock markets 18:00:00 29/11/2024 GMT			5-day change	1st Jan Change
92.58 ^USD	+0.18%		+2.65%	+14.28%

11-27	Gilead Sciences, Inc. Announces New England Journal of Medicine Publication of PURPOSE 2 Results	CI
11-22	UBS Raises Price Target on Gilead Sciences to $96 From $70, Maintains Neutral Rating	MT

Gilead Sciences, Inc. Announces New England Journal of Medicine Publication of PURPOSE 2 Results	11-27	CI
UBS Raises Price Target on Gilead Sciences to $96 From $70, Maintains Neutral Rating	11-22	MT
Mizuho Securities Adjusts Price Target on Gilead Sciences to $100 From $90	11-20	MT
Gilead Sciences, Inc. Presents at Jefferies London Healthcare Conference 2024, Nov-20-2024 09:30 AM	11-20
Daiwa Securities Adjusts Gilead Sciences Price Target to $90 From $73	11-18	MT
RBC Capital Adjusts Gilead Sciences Price Target to $84 From $81	11-18	MT
IDEAYA Biosciences, Inc. Appoints Stu Dorman as Chief Commercial Officer	11-18	CI
Gilead Sciences Says Most of Phase 3 Primary Biliary Cholangitis Participants Treated With Livdelzi Achieved Biochemical Response	11-15	MT
Gilead's Livdelzi Demonstrated A Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis	11-15	CI
Wolfe Research Initiates Gilead Sciences at Outperform With $110 Price Target	11-15	MT
Gilead Sciences Prices $3.5 Billion Senior Notes Offering	11-14	MT
Gilead Sciences Says Investigational HIV Prevention Drug Showed High Infection Reduction	11-13	MT
Gilead Sciences, Inc. Presents Full Purpose 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow	11-13	CI
Maxim Downgrades Gilead Sciences to Hold From Buy	11-08	MT
Truist Securities Raises Price Target on Gilead Sciences to $97 From $83, Maintains Hold Rating	11-08	MT
Raymond James Adjusts Gilead Sciences Price Target to $103 From $95, Maintains Outperform Rating	11-07	MT
JPMorgan Adjusts Price Target on Gilead Sciences to $105 From $100, Maintains Overweight Rating	11-07	MT
Barclays Adjusts Price Target on Gilead Sciences to $95 From $84, Maintains Equalweight Rating	11-07	MT
TD Cowen Adjusts Price Target on Gilead Sciences to $95 From $85, Maintains Buy Rating	11-07	MT
BMO Capital Adjusts Price Target on Gilead Sciences to $102 From $94, Maintains Outperform Rating	11-07	MT
Oppenheimer Adjusts Price Target on Gilead Sciences to $105 From $95, Maintains Outperform Rating	11-07	MT
Piper Sandler Adjusts Price Target on Gilead Sciences to $105 From $95, Maintains Overweight Rating	11-07	MT
Wells Fargo Adjusts Price Target on Gilead Sciences to $105 From $100, Maintains Overweight Rating	11-07	MT
RBC Capital Adjusts Price Target on Gilead Sciences to $81 From $75, Maintains Sector Perform Rating	11-07	MT
Goldman Sachs Adjusts Price Target on Gilead Sciences to $84 From $74, Maintains Neutral Rating	11-07	MT

Gilead Sciences, Inc.

Equities